Tanlor (Methocarbamol) Patent Expiration, LOE Window & CMS Spending

Tanlor (Methocarbamol) by Forte Bio-: Off-Patent Genericized (AB Competition), 2 AB generics, $509K 2024 CMS Part D & Medicaid spend, and $2,350 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorForte Bio-
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$509K
2024 Medicare Part D Spend$84K
2024 Medicaid Spend$426K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,350 intro WAC)